Oncoswift® Frontier
Test Description and clinical significance
Disease:
Solid tumors
Testing is limited to 50 gene set + TMB, MSI, and LOH in the event that Tier 1 (Strong
Clinical Significance) genomic alterations are detected. HRR gene coverage is limited,
Oncoswift® Frontier is therefore not appropriate for PARPi therapy prediction or testing
in gynecologic neoplasms, pancreatic, or prostatic adenocarcinomas
Specimen Requirements
Collection:
FFPE sections, 5-10 sections are recommended at 4 to 10 micron. A minimum of 20 μL of each DNA with a concentration of at least 5 ng/μL and an OD260/280 ratio of 1.7-1.9, obtained on a spectrophotometer is required.
Stability:
FFPE blocks- Indefinitely/ FFPE Slides-4 weeks
Unacceptable Conditions:
Specimen submitted is in the incorrect fixative. Insufficient specimen (less than 10% of tumor). Unlabeled or improperly labeled specimens. Decalcified specimens. Improperly stored DNA.
Storage & Transport
Store FFPE blocks and slides at room temperature. Slides may be stored at ambient temperature for up to 4 weeks prior to DNA extraction. Genomic DNA must be stored at 2–8°C for several weeks post extraction, then at –15 to –25°C for long term.
CPT(s)
"50 genes: 81445 500 genes: 81455, 81459 (including MSI and TMB), G0452(26), 88381"
New York Approved
YES
TAT
≤ 4-5 Days
*The CPT codes provided are for informational purposes only and are based on AMA guidelines The billing party is solely responsible for correct CPT coding.
